Global Molecular Diagnostics for Cancer Markets Report 2021-2025: Market is Positioned to Directly Benefit from the Explosion in Genomics but Shifting Resources to COVID May Interrupt Growth

2021-04-30

基因疗法合作

Dublin, April 30, 2021 (GLOBE NEWSWIRE) -- The "Molecular Diagnostics for Cancer 2021-2025: Markets Forecasts by Cancer Type, Product, and Place with Executive & Consultant Guides and Customization" report has been added to ResearchAndMarkets.com's offering. A market with fundamental growth factors is impacted by the COVID-19 Pandemic. Molecular Diagnostics for Cancer is positioned to directly benefit from the explosion in genomics knowledge but shifting resources to deal with the COVID emergency may interrupt growth. Learn all about it in this new report. It includes a special segment Cancer Companion Diagnostics Cancer Companion Diagnostics, a new segment of the market that is reshaping the industry, and now over 130 companies are profiled. A range of dynamic trends are pushing market growth and company valuations. Trends like: Working against this dynamic market are the forces of the COVID Driven Recession. The latest numbers in this report factor in the different COVID forces and their timing, and their effect on growth. Exciting technical developments especially in the area of pharmacogenics hold the promise of a dynamic, growing and evolving world market that is moving out of the national and regional orientation and onto a global stage. In addition to customization work, breakouts for particular segments, assistance and support is included free of charge. This report provides data that analysts and planners can use. Hundreds of pages of information including a complete list of Current 2021 United States Medicare Fee Payment Schedules to help understand test pricing in detail. Make facilities planning decisions. Forecast demand for new testing regimes or technologies. Make research investment decisions. Assistance in providing specific growth and market size estimates for new technology tests is provided. Existing laboratories and hospitals can use the information directly to forecast and plan for clinical facilities growth. Key Topics Covered: 1 Molecular Dx Oncology Market - Strategic Situation Analysis with Impact of the COVID-19 Pandemic 2 Guide for Executives, Marketing, Sales and Business Development Staff 3 Guide for Management Consultants and Investment Advisors 4 Introduction and Market Definition4.1 What is Molecular Diagnostics4.2 The Diagnostics Revolution4.3 Market Definition4.3.1 Revenue Market Size4.4 Methodology4.5 U.S. Medical Market and laboratory Testing - Perspective4.5.1 U.S. Medicare Expenditures for Laboratory Testing 5 Market Overview5.1 Market Participants5.1.1 Academic Research Lab5.1.2 Diagnostic Test Developer5.1.3 Genomic Instrumentation Supplier5.1.4 Cell Separation and Viewing Instrumentation Supplier.5.1.5 Pharmaceutical/Reagent Supplier5.1.6 Independent Testing Lab5.1.7 Public National/Regional Lab5.1.8 Hospital lab5.1.9 Physician Lab5.1.10 Audit Bodies5.1.11 Certification Body5.2 Market Segments5.2.1 Traditional Market Segmentation5.2.2 Laboratory Focus and Segmentation5.3 Industry Structure5.3.1 Hospital Testing Share5.3.2 Economies of Scale5.3.3 Physician Office Labs5.3.4 Physicians and POCT 6 Market Trends6.1 Factors Driving Growth6.1.1 New Diagnostics Create New Markets6.1.2 New Roles for Diagnostics6.1.3 Longevity and Outcomes6.1.4 Expanding the Pharmaceutical Toolbox6.1.5 Regulatory Retreat6.2 Factors Limiting Growth6.2.1 Falling Prices6.2.2 Lower Costs6.2.3 COVID Pandemic6.2.4 Wellness has a Downside6.3 Instrumentation and Automation6.3.1 Instruments Key to Market Share6.3.2 Bioinformatics Plays a Role6.4 Diagnostic Technology Development6.4.1 Next Generation Sequencing6.4.2 Shifting Role of Diagnostics6.4.3 Multiplexing and Foundation One6.4.4 Pharmacogenomics Technology6.4.5 Whole Genome Sequencing6.4.6 Gene Editing and Gene Therapy 7 Molecular Diagnostics Recent Developments7.1 Recent Developments - Importance and How to Use This Section7.1.1 Importance of These Developments7.1.2 How to Use This Section7.2 Nucleix to Invest in Early-Stage Lung Cancer Dx7.3 Invitae to Acquire Genosity for $200M7.4 Bio-Techne Obtains CE Mark for Exosomal Liquid Biopsy Prostate Test7.5 Agilent Technologies to Acquire Liquid Biopsy Firm Resolution Bioscience7.6 Natera Revenues Grow 35 Percent7.7 AnchorDx Closes $40M Financing Round7.8 Exact Sciences Strategy for End-to-End Cancer Testing7.9 Genomics England: Whole Genome Sequencing for Cancer Patients to Launch7.10 Singlera Genomics Closes $150M Funding for Cancer Screening7.11 Biocartis GeneproDx, Endpoint Health Collaborate on Tests for Idylla Platform7.12 Wales to Routinely Screen Cancer Patients With Yourgene Elucigene Test7.13 Metastatic Cancer Markers Identified in Clinical WGS Study7.14 Stitch Bio Bets on CRISPR Tech7.15 Bayer, LifeLabs Launch Free NTRK Genetic Testing Program7.16 Foundation Medicine Liquid Biopsy Gets FDA Approval for Multiple Companion Dx7.17 Progress, Challenges in Liquid Biopsy Reimbursement7.18 Israeli Startup Curesponse Raises $6M7.19 Coronavirus Pandemic Bites into European Cancer Research7.20 Veracyte's Prosigna IDs Patients Likely to Benefit from Aggressive Chemotherapy7.21 Combining CRISPR and Nanopore Sequencing7.22 Liquid Biopsy Detects Cancer Early via Cell Clusters7.23 Roche, Illumina unveil 15-year cancer diagnostic tie-up7.24 Saga, Servier Sign Liquid Biopsy Services Deal7.25 Home urine test could revolutionize diagnosis of prostate cancer7.26 Cancer Gene Tests Cost-Effective for Breast Cancer Patients7.27 Personal Genome Diagnostics Gets CE Mark for Elio Tissue Assay7.28 OncoCyte to Buy Cancer Testing Company Razor Genomics7.29 Blood Test May Eliminate Need for Exploratory Surgery7.30 NGS Cancer Panel Receives New York State Conditional Approval7.31 Biocartis Inks Cancer CDx Deal With Bristol-Myers Squibb 8 Profiles of Key MDx Companies8.1 10x Genomics, Inc.8.2 Abbott Diagnostics8.3 AccuraGen Inc.8.4 Adaptive Biotechnologies8.5 Aethlon Medical8.6 Agena Bioscience, Inc.8.7 Agilent8.8 Anchor Dx8.9 ANGLE plc8.10 ApoCell, Inc.8.11 ArcherDx, Inc.8.12 ARUP Laboratories8.13 Asuragen8.14 AVIVA Biosciences8.15 Baylor Miraca Genetics Laboratories8.16 Beckman Coulter, Inc.8.17 BGI Genomics Co. Ltd.8.18 Bioarray Genetics8.19 Biocartis8.20 Biocept, Inc.8.21 Biodesix Inc.8.22 BioFluidica8.23 BioGenex8.24 Biolidics Ltd.8.25 bioMerieux Diagnostics8.26 Bioneer Corporation8.27 Bio-Rad Laboratories, Inc.8.28 Bio-Reference Laboratories8.29 Bio-Techne8.30 Bioview8.31 Bolidics8.32 Boreal Genomics8.33 Bristol-Myers Squibb8.34 Cancer Genetics8.35 Caris Molecular Diagnostics8.36 CellMax Life8.37 Cepheid (now Danaher)8.38 Charles River Laboratories8.39 Chronix Biomedical8.40 Circulogene8.41 Clinical Genomics8.42 Cynvenio8.43 Cytolumina Technologies Corp.8.44 CytoTrack8.45 Datar Cancer Genetics Limited8.46 Diagnologix LLC8.47 Diasorin S.p.A.8.48 Enzo Life Sciences, Inc.8.49 Epic Sciences8.50 Epigenomics AG8.51 Eurofins Scientific8.52 Exosome Diagnostics8.53 Exosome Sciences8.54 Fabric Genomics8.55 Fluidigm Corp8.56 Fluxion Biosciences8.57 Foundation Medicine8.58 Freenome8.59 FUJIFILM Wako Diagnostics8.60 GeneFirst Ltd.8.61 Genetron Health (Beijing) Co. Ltd.8.62 Genomic Health8.63 GenomOncology8.64 GILUPI Nanomedizin8.65 Grail, Inc.8.66 Guardant Health8.67 HalioDx8.68 HansaBiomed8.69 HeiScreen8.70 Helomics8.71 Horizon Discovery8.72 HTG Molecular Diagnostics8.73 iCellate8.74 Illumina8.75 Incell Dx8.76 Inivata8.77 Integrated Diagnostics8.78 Invivogen8.79 Invivoscribe8.80 Janssen Diagnostics8.81 MDNA Life SCIENCES, Inc.8.82 MDx Health8.83 Menarini Silicon Biosystems8.84 Millipore Sigma8.85 Miltenyi Biotec8.86 MIODx8.87 miR Scientific8.88 Molecular MD8.89 MyCartis8.90 Myriad Genetics/Myriad RBM8.91 NantHealth, Inc.8.92 Natera8.93 NeoGenomics8.94 New Oncology8.95 Novogene Bioinformatics Technology Co. Ltd.8.96 Oncocyte8.97 OncoDNA8.98 Ortho Clinical Diagnostics8.99 Oxford Nanopore Technologies8.100 Panagene8.101 Perkin Elmer8.102 Personal Genome Diagnostics8.103 Personalis8.104 Precipio8.105 PrecisionMed8.106 Promega8.107 Qiagen Gmbh8.108 Rarecells SAS8.109 RareCyte8.110 Roche Molecular Diagnostics8.111 Screencell8.112 Sense Biodetection.8.113 Serametrix8.114 Siemens Healthineers8.115 Silicon Biosystems8.116 simfo GmbH8.117 Singlera Genomics Inc.8.118 Singulomics8.119 SkylineDx8.120 Stratos Genomics8.121 Sysmex Inostics8.122 Tempus Labs, Inc.8.123 Thermo Fisher Scientific Inc.8.124 Thrive Earlier Detection8.125 Todos Medical8.126 Trovagene8.127 Volition8.128 Vortex Biosciences 9 The Global Market for MDx Cancer9.1 MDx Cancer - Global Market Overview by Country9.2 Global Market by Cancer Type - Overview9.3 Global Market by Product Type - Overview9.4 Global Market by Place - Overview10. Global Market by Cancer Type10.1 MDx Breast Cancer10.2 MDx Colorectal Cancer10.3 MDx Cervical Cancer10.4 MDx Lung Cancer10.5 MDx Prostate10.6 MDx Melanoma Cancer10.7 MDx Blood10.8 MDx Companion Dx Development11. Global Market by Product Type11.1 MDx Instruments11.2 MDx Reagents11.3 MDx Software and Services12. Global Market by Place12.1 MDx Clinical Laboratory12.2 MDx Pharmaceutical12.3 MDx Research 13 Cancer Treatment and Trials13.1 FDA Cancer Drug Approvals by Year13.2 Clinical Trials Started 2010 to 201613.3 Prevalence of Cancer Treatments - 2015 14 Appendices14.1 United States Medicare System: January 2021 Clinical Laboratory Fees Schedule14.2 FDA Approved Human Genetic Tests14.3 FDA Approved Microbial Tests14.4 FDA Approved Pharmacogenomics Tests For more information about this report visit

机构